Washington, DC—A new report released by the Ovarian Cancer National Alliance summarizes the experiences of 1,014 women diagnosed with ovarian cancer. Based on a survey conducted by the Alliance in … Continued
Dr. Maria Barbolina is a 2013 Liz Tilberis Early Career Award grant recipient. In this interview with OCRF’s Sarah DeFeo, Dr. Barolina discusses her research and what it means to receive … Continued
An ovarian cancer survivor in Australia, Vali, is 26-weeks pregnant after being told she was infertile due to ovarian cancer treatments. “The sample of Vali’s ovarian tissue was taken from … Continued
A new OCRF-funded study from researchers at the University of Michigan Comprehensive Cancer Center found that a subset of immune cells, called myeloid derived suppressor cells, do more harm than … Continued
Researchers in the UK have identified a gene in mice that, if faulty, may increase the chance of developing a rare type of ovarian cancer. The findings were published in the … Continued
An index created at The University of Texas MD Anderson Cancer Center in Houston, based on protein biomarkers was able to discriminate between women at high risk and low risk for … Continued
The Washington Post explores new options for young women going through cancer treatment who want to know about their options for having children after treatment. The article looks at emerging … Continued
Building on previously presented work, researchers at M.D. Anderson Cancer Center in Houston have published new findings that show that evaluating the change of CA-125 over time shows promise as … Continued
In a review article published online in Oncogene on August 12, OCRF-funded researchers provide a comprehensive review of pre-clinical models used in ovarian cancer research. The authors, including OCRF grantees … Continued
Two dogs at the University of Pennsylvania’s Penn Vet Working Dog Center are learning how to smell tissue that is in early stages of ovarian cancer. The dogs have been … Continued
Researchers in Austria investigated whether the time interval from surgery to start of chemotherapy has an impact on clinical outcome in patients with advanced serous ovarian cancer. Data from 191 patients … Continued
Dr. Coleman, a member of the Alliance’s Scientific and Medical Advisory Board, conducted an interview on ovarian cancer therapies for the Cancer Network. He discussed the heterogeneity of ovarian cancer, … Continued
Get email updates about research news, action alerts, and ways to join the fight.
